V. V. Yakusevich

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

H. Bachelez, P.C.M. van de Kerkhof, Robert Strohal et al. · The Lancet · 2015 · 388 citations · Full text

Autoimmune Disease, Clinical Trials, Inflammatory Marker +7

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

Claudia Pena-Rossi, Marina Stanislav, V. V. Yakusevich et al. · Lupus · 2009 · 111 citations · Full text

Immunology, Pharmacotherapy, Human Immunoglobulin +19

Long‐term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)—results from the European phase 3 open‐label safety trial

Jan Tack, Juris Pokrotnieks, Gediminas Urbonas et al. · Neurogastroenterology & Motility · 2018 · 51 citations · Full text

Pain Disorders, Pain Medicine, Pharmacotherapy +21

Microcirculation and blood rheology abnormalities in chronic heart failure

A. V. Muravyov, Alexandr Petrochenko, V. V. Yakusevich et al. · Clinical Hemorheology and Microcirculation · 2016 · 31 citations